PubRank

J R Ballinger

Author PubWeight™ 36.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adverse events in nuclear medicine - cause for concern? Eur J Nucl Med Mol Imaging 2012 1.41
2 31P changes as a measure of therapy response in human osteosarcomas implanted into nude mice. Magn Reson Imaging 1994 1.40
3 Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 2001 1.39
4 Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study. Stroke 2004 1.14
5 Sentinel node detection and definition may depend on the imaging agent and timing. Clin Nucl Med 1999 1.12
6 A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres. J Control Release 2001 1.07
7 Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 1996 1.04
8 The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer 2000 0.93
9 99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. Nucl Med Commun 1999 0.92
10 Susceptibility artifact reduction in fat suppression. Magn Reson Med 1995 0.90
11 Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 1998 0.88
12 Clinical use of technetium-99m HM-PAO for determination of brain death. J Nucl Med 1989 0.88
13 Imaging inflammation with 99Tcm-labeled chemotactic peptides: analogues with reduced neutropenia. Nucl Med Commun 1996 0.88
14 Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein. Cancer Biother Radiopharm 2001 0.87
15 SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 1999 0.87
16 Routine determination of radiochemical purity of 99mTc-MIBI. Int J Rad Appl Instrum A 1989 0.86
17 Physiologic modeling of PET data: quantitative conflict and challenge. J Nucl Med 1997 0.84
18 Regional differences in technetium-99m-ECD clearance on brain SPECT in healthy subjects. J Nucl Med 1997 0.83
19 Variation in lymphatic function may predispose to development of breast cancer-related lymphoedema. Eur J Surg Oncol 2004 0.82
20 SPECT imaging of dopamine receptors. J Nucl Med 1996 0.82
21 Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. Int J Cancer 1999 0.81
22 Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Br J Cancer 2001 0.81
23 The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies. Clin Exp Immunol 2007 0.80
24 Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data. J Nucl Med 1999 0.80
25 From graphical analysis to multilinear regression analysis of reversible radioligand binding. J Cereb Blood Flow Metab 1996 0.80
26 BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000 0.80
27 Labelling small quantities of monoclonal antibodies and their F(ab')2 fragments with technetium-99m. Nucl Med Biol 1995 0.79
28 Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann Nucl Med 1993 0.79
29 Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys 1998 0.79
30 Radiochemical purity of [99mTc]HM-PAO. J Nucl Med 1988 0.79
31 Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 1993 0.79
32 Lymphatic transfer studies with immunoglobulin scintigraphy after axillary surgery. Eur J Surg Oncol 2007 0.79
33 Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med 1997 0.78
34 Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000 0.78
35 In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors. Cancer Biother Radiopharm 2000 0.77
36 Tissue-to-blood transport of radiolabelled immunoglobulin injected into the web spaces of the hands of normal subjects and patients with breast cancer-related lymphoedema. J Vasc Res 2004 0.77
37 A novel anti-seminoma monoclonal antibody (M2A) labelled with technetium-99m: potential application for radioimmunoscintigraphy. Br J Urol 1995 0.77
38 Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity. Bioconjug Chem 2000 0.76
39 A pilot study of dual-isotope lymphoscintigraphy for breast sentinel node biopsy comparing intradermal and intraparenchymal injection. Eur J Surg Oncol 2009 0.76
40 Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime. Nucl Med Biol 2001 0.76
41 BMS181321 accumulation in rodent and human cells: the role of P-glycoprotein. Br J Cancer Suppl 1996 0.75
42 Cerebral perfusion imaging with technetium-99m HMPAO following cerebral trauma. Initial experience. Clin Nucl Med 1990 0.75
43 Accumulation of sestamibi in lymphoma cell lines in vitro. Leuk Lymphoma 2000 0.75
44 In vitro comparison of HMPAO and gentisic acid for labelling leukocytes with 99mTc. Eur J Nucl Med 1990 0.75
45 Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia. Biochem Pharmacol 2000 0.75
46 A solid-phase technique for preparation of no-carrier-added technetium-99m radiopharmaceuticals: application to the streptavidin/biotin system. Nucl Med Biol 2000 0.75
47 A novel amine-dioxime chelator for technetium-99m: synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells. Bioconjug Chem 2000 0.75
48 Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics. Biochem Pharmacol 1997 0.75
49 Optimized radiolabelling of pig granulocytes with indium-111 tropolonate. Int J Rad Appl Instrum B 1990 0.75
50 Decomposition of Tc-99m pyrophosphate by peroxides in pertechnetate used in preparation. J Nucl Med 1981 0.75
51 External radioactive reference markers in SPECT imaging of the dopamine system. J Nucl Med Technol 1999 0.75
52 Cerebral perfusion imaging. J Nucl Med 1987 0.75
53 Mechanisms that contribute to the in vitro relaxation and signal intensity of water in barium sulfate suspensions used as MRI contrast agents. Magn Reson Imaging 1993 0.75
54 Synthesis and characterization of surface-hydrophobic ion-exchange microspheres and the effect of coating on drug release rate. J Pharm Sci 2000 0.75
55 Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. Breast Cancer Res Treat 1998 0.75
56 A potentially artifact-free oral contrast agent for gastrointestinal MRI. Magn Reson Med 1993 0.75
57 Power efficient on-resonance saturation pulses for magnetization transfer in magnetic resonance imaging. Magn Reson Med 1996 0.75
58 In vivo animal tests of an artifact-free contrast agent for gastrointestinal MRI. Magn Reson Imaging 1997 0.75
59 Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia. Bioconjug Chem 1999 0.75
60 Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technology. Bioconjug Chem 1999 0.75
61 A kit for labelling erythrocytes or leukocytes with technetium-99m. Int J Rad Appl Instrum B 1990 0.75
62 Nuclear medicine detection of inflammation and infection. Curr Opin Radiol 1991 0.75
63 Evaluation of reduction-mediated labelling of antibodies with technetium-99m. Int J Rad Appl Instrum B 1992 0.75